https://www.selleckchem.com/products/shield-1.html
The 5-year RFS for patients aged ≥75 years or with lymphovascular involvement were 94.4% (95% CI 89.8-97. and 95.1% (95% CI 92.5-96.8), respectively. The survival outcomes of pT1N0-3 and pT2-3N0 were excellent, even in patients with aged 75 years or lymphovascular involvement which were risk factors. However, the sample size of T1N3 gastric cancer is small, so larger sample size and risk factor analysis are required. 75 years or lymphovascular involvement which were risk factors. However, the sample size of T1N3 gastric cancer is
Curtir
Comentario
Compartilhar
